BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 24643932)

  • 1. Development of EGFR-targeted nanoemulsion for imaging and novel platinum therapy of ovarian cancer.
    Ganta S; Singh A; Patel NR; Cacaccio J; Rawal YH; Davis BJ; Amiji MM; Coleman TP
    Pharm Res; 2014 Sep; 31(9):2490-502. PubMed ID: 24643932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Formulation development of a novel targeted theranostic nanoemulsion of docetaxel to overcome multidrug resistance in ovarian cancer.
    Ganta S; Singh A; Rawal Y; Cacaccio J; Patel NR; Kulkarni P; Ferris CF; Amiji MM; Coleman TP
    Drug Deliv; 2016; 23(3):968-80. PubMed ID: 24901206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EGFR Targeted Theranostic Nanoemulsion for Image-Guided Ovarian Cancer Therapy.
    Ganta S; Singh A; Kulkarni P; Keeler AW; Piroyan A; Sawant RR; Patel NR; Davis B; Ferris C; O'Neal S; Zamboni W; Amiji MM; Coleman TP
    Pharm Res; 2015 Aug; 32(8):2753-63. PubMed ID: 25732960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, Synthesis, and Characterization of Folate-Targeted Platinum-Loaded Theranostic Nanoemulsions for Therapy and Imaging of Ovarian Cancer.
    Patel NR; Piroyan A; Nack AH; Galati CA; McHugh M; Orosz S; Keeler AW; O'Neal S; Zamboni WC; Davis B; Coleman TP
    Mol Pharm; 2016 Jun; 13(6):1996-2009. PubMed ID: 27170232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphatidylinositol 3-kinase inhibitor (PIK75) containing surface functionalized nanoemulsion for enhanced drug delivery, cytotoxicity and pro-apoptotic activity in ovarian cancer cells.
    Talekar M; Ganta S; Singh A; Amiji M; Kendall J; Denny WA; Garg S
    Pharm Res; 2012 Oct; 29(10):2874-86. PubMed ID: 22653667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In Vitro and In Vivo evaluation of a novel folate-targeted theranostic nanoemulsion of docetaxel for imaging and improved anticancer activity against ovarian cancers.
    Patel NR; Piroyan A; Ganta S; Morse AB; Candiloro KM; Solon AL; Nack AH; Galati CA; Bora C; Maglaty MA; O'Brien SW; Litwin S; Davis B; Connolly DC; Coleman TP
    Cancer Biol Ther; 2018 Jul; 19(7):554-564. PubMed ID: 29737910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-encapsulation of paclitaxel and C6 ceramide in tributyrin-containing nanocarriers improve co-localization in the skin and potentiate cytotoxic effects in 2D and 3D models.
    Carvalho VFM; Migotto A; Giacone DV; de Lemos DP; Zanoni TB; Maria-Engler SS; Costa-Lotufo LV; Lopes LB
    Eur J Pharm Sci; 2017 Nov; 109():131-143. PubMed ID: 28735040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and antitumour activity of a new trinuclear platinum compound [{cis-PtCl(NH3)2μ {trans-Pt(3-hydroxypyridine)2H2N(CH2)5NH2)2}] Cl4 in human ovarian cancer cells.
    Hamad SA; Beale P; Yu JQ; Huq F
    Anticancer Res; 2014 Apr; 34(4):1923-9. PubMed ID: 24692727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis of a monofunctional platinum compound and its activity alone and in combination with phytochemicals in ovarian tumor models.
    Arzuman L; Beale P; Yu JQ; Proschogo N; Huq F
    Anticancer Res; 2014 Dec; 34(12):7077-90. PubMed ID: 25503135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ONC201 induces the unfolded protein response (UPR) in high- and low-grade ovarian carcinoma cell lines and leads to cell death regardless of platinum sensitivity.
    Rumman M; Buck S; Polin L; Dzinic S; Boerner J; Winer IS
    Cancer Med; 2021 May; 10(10):3373-3387. PubMed ID: 33932119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human ovarian cancers.
    Alberts DS; Fanta PT; Running KL; Adair LP; Garcia DJ; Liu-Stevens R; Salmon SE
    Cancer Chemother Pharmacol; 1997; 39(6):493-7. PubMed ID: 9118460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced Cytotoxicity of Folic Acid-Targeted Liposomes Co-Loaded with C6 Ceramide and Doxorubicin: In Vitro Evaluation on HeLa, A2780-ADR, and H69-AR Cells.
    Sriraman SK; Pan J; Sarisozen C; Luther E; Torchilin V
    Mol Pharm; 2016 Feb; 13(2):428-37. PubMed ID: 26702994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro.
    Yanagie H; Hisa T; Ogata A; Miyazaki A; Nonaka Y; Nishihira T; Osada I; Sairennji T; Sugiyama H; Furuya Y; Kidani Y; Takamoto S; Takahashi H; Eriguchi M
    Biomed Pharmacother; 2009 Sep; 63(8):553-60. PubMed ID: 18571892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Costunolide induces apoptosis in platinum-resistant human ovarian cancer cells by generating reactive oxygen species.
    Yang YI; Kim JH; Lee KT; Choi JH
    Gynecol Oncol; 2011 Dec; 123(3):588-96. PubMed ID: 21945308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis of tris(quinoline)monochloroplatinum(II) Chloride and its Activity Alone and in Combination with Capsaicin and Curcumin in Human Ovarian Cancer Cell Lines.
    Arzuman L; Beale P; Yu JQ; Huq F
    Anticancer Res; 2016 Jun; 36(6):2809-18. PubMed ID: 27272792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination effects of platinum drugs and N1, N11 diethylnorspermine on spermidine/spermine N1-acetyltransferase, polyamines and growth inhibition in A2780 human ovarian carcinoma cells and their oxaliplatin and cisplatin-resistant variants.
    Tummala R; Diegelman P; Hector S; Kramer DL; Clark K; Zagst P; Fetterly G; Porter CW; Pendyala L
    Cancer Chemother Pharmacol; 2011 Feb; 67(2):401-14. PubMed ID: 20443003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanistic Nanotherapeutic Approach Based on siRNA-Mediated DJ-1 Protein Suppression for Platinum-Resistant Ovarian Cancer.
    Schumann C; Chan S; Khalimonchuk O; Khal S; Moskal V; Shah V; Alani AW; Taratula O; Taratula O
    Mol Pharm; 2016 Jun; 13(6):2070-83. PubMed ID: 27170529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GSH-sensitive Pt(IV) prodrug-loaded phase-transitional nanoparticles with a hybrid lipid-polymer shell for precise theranostics against ovarian cancer.
    Huang H; Dong Y; Zhang Y; Ru D; Wu Z; Zhang J; Shen M; Duan Y; Sun Y
    Theranostics; 2019; 9(4):1047-1065. PubMed ID: 30867815
    [No Abstract]   [Full Text] [Related]  

  • 19. Carboplatin prodrug conjugated Fe
    Song H; Quan F; Yu Z; Zheng M; Ma Y; Xiao H; Ding F
    J Mater Chem B; 2019 Jan; 7(3):433-442. PubMed ID: 32254730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential cytotoxicity, uptake and DNA binding of tetraplatin and analogous isomers in sensitive and resistant cancer cell lines.
    Kido Y; Khokhar AR; Siddik ZH
    Anticancer Drugs; 1993 Apr; 4(2):251-8. PubMed ID: 8490203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.